Table 5 Inflammatory parameters before and after 8 weeks of HPN
Inflammatory parameter | Test group (MCT/LCT/n-3 PUFA) N = 11 | Control group (MCT/LCT) N = 11 |
|---|---|---|
IL-6 (ng/L) | ||
 (reference range < 5 ng/L) | ||
  Baseline | 5.473 ± 2.501 | 7.050 ± 5.432 |
  V2 (8 weeks HPN) | 9.145 ± 8.614 | 4.364 ± 2.448 |
Mean treatment difference (V2-BL) = 4.8 ng/L, CI 95 [− 0.5; 10.1], p = 0.0745, t-test | ||
IL-10 (ng/L) | ||
 (reference range < 5 ng/L) | ||
  Baseline | 5.000 ± 0.000 | 5.033 ± 0.115 |
  V2 (8 weeks HPN) | 5.000 ± 0.000 | 5.027 ± 0.090 |
Mean treatment difference (V2-BL) = − 0.03 ng/L, CI 95 [− 0.09; 0.03], p = 0.3062, t-test | ||
TNF-alpha (ng/L) | ||
 (reference range < 15 ng/L) | ||
  Baseline | 11.918 ± 6.506 | 13.175 ± 6.996 |
  V2 (8 weeks HPN) | 10.673 ± 4.382 | 10.645 ± 4.457 |
Mean treatment difference (V2-BL) = 0.9 ng/L, CI 95 [− 2.5; 4.3], p = 0.5801, t-test | ||
CRP (mg/dL)* | ||
 (reference range < 0.50 mg/dL) | ||
  Baseline | 0.691 ± 0.595 | 0.977 ± 1.370 |
  V2 (8 weeks HPN) | 1.453 ± 1.903 | 0.745 ± 0.541 |
Mean treatment difference (V2-BL) = 0.6 mg/L, CI 95 [− 0.4; 1.6], p = 0.2231, t-test | ||